Park Square has placed Stephen Basso as Chief Financial Officer at Cybrexa Therapeutics.
| less than a minute read
Cybrexa Therapeutics Appoints Stephen Basso as Chief Financial Officer
Get in touch
Get in touch
Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ Peptide Drug Conjugate (PDC) tumor targeting platform, today announced that it has appointed pharmaceutical and financial services veteran Stephen Basso as Chief Financial Officer.
Get in touch
Get in touch
Latest Insights
/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/2026-09-01-21-26-53-841-6a97431d406533fea8d4615c.gif)
/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/2026-09-01-15-07-30-357-6a96ea32ce35c90f7ee74028.jpg)
/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/2026-08-24-14-26-15-201-6a8c5487b4553f6e28c0bcb7.jpg)
/Passle/58a5cb8db00e8110e83aa395/SearchServiceImages/2026-08-19-20-29-57-758-6a8612450e2b381c3863fcf2.jpg)